Also known as cjc-1295 dac, dac-grf(1–29) · Wikipedia
CJC-1295 with DAC (DAC-GRF(1-29)) is a tetrasubstituted analog of human GHRH(1-29) bearing a Drug Affinity Complex - a maleimidopropionyl-lysine at the C-terminus that forms a covalent bond with cysteine-34 of circulating serum albumin, converting the molecule into a long-acting depot (https://pubmed.ncbi.nlm.nih.gov/15817669/). Originally developed by ConjuChem and advanced to Phase II, CJC-1295 produces sustained elevations of GH and IGF-1 lasting days to weeks per injection (https://pubmed.ncbi.nlm.nih.gov/19386527/). Clinical development was discontinued and the molecule is sold only as a research chemical. It is WADA-prohibited and not FDA-approved for any indication. Also known as: CJC-1295 DAC; DAC-GRF(1-29).
—
best
price
—
per
mg
—
vendors
tracked
Phase II
stage
Vendor data
Per-vendor pricing and verification tiers populate as the SavePeptides crawler comes online. Until then, browse all approved vendors directly.
Browse all vendorsMechanism of action
CJC-1295 with DAC is the same tetrasubstituted (D-Ala2, Gln8, Ala15, Leu27) GHRH(1-29) analog as mod-GRF, modified at the C-terminus with a maleimidopropionic-acid lysine (Drug Affinity Complex) that covalently binds Cys-34 of serum albumin via Michael addition (https://pubmed.ncbi.
Pharmacokinetic properties
Half-life
~6-8 days (due to albumin binding)
Routes
subcutaneous
Bioavailability
Long-acting depot effect via covalent albumin conjugation; once- or twice-weekly dosing typical.
Amino-acid sequence
Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg (C-terminal Lys modified with maleimidopropionyl (DAC))
Use & research dosing
Original ConjuChem Phase I/II trials in healthy adults used single SC doses of 60, 90, 125, and 250 mcg/kg, producing dose-dependent GH peaks and sustained IGF-1 elevation for 6-11 days post-injection (https://pmc.ncbi.nlm.nih.gov/articles/PMC2787983/). Self-experimentation protocols typically report fixed doses of 1-2 mg subcutaneously per week, often split into 500 mcg to 1 mg twice weekly. There is no FDA-approved dose; clinical development was halted at Phase II and the molecule is sold only as a research chemical.
Research-use framing only. SavePeptides sells nothing for human consumption. Doses above reflect reported research / self-experimentation ranges, not clinical recommendations.
The defining feature of CJC-1295 with DAC is its sustained non-pulsatile GH elevation, which differs fundamentally from endogenous pulsatile GHRH and from short-acting GHRH analogs like mod-GRF/sermorelin. Many protocol authors prefer the no-DAC version specifically to preserve physiologic pulsatility. Clinical development was discontinued after Phase II for reasons not fully detailed in peer-reviewed literature; this is the principal reason the molecule remains a research chemical despite well-characterized pharmacology in the published Phase I/II reports.
— SavePeptides editorial desk · last updated 2026-05-25
Cautions & contraindications
Research foundation
Facts verified
2026-05-25
Confidence
medium
What this means
Vendor data coming soon
001 — Independent
SavePeptides lists vendors after an initial review and distinguishes verified vendors where additional checks have been completed. We may earn commissions from referral links, and sponsored placements will be clearly disclosed.
002 — Vendor-funded
SavePeptides is free for buyers. We may earn a commission when you order through our links, but we do not lock deals behind a paywall, require an email to view codes, or inflate comparison prices.
003 — Research use
SavePeptides surfaces vendor, pricing, and coupon information for research compounds. These products are not intended, approved, or recommended for human consumption. Our content is informational only and does not constitute medical advice.